Patients in Ireland living with Friedreich's ataxia are bracing for delays before they can actually receive Skyclarys, even though the drug has been cleared for reimbursement. Approval on paper does not put the medicine in their hands, and that gap is what worries them most. Skyclarys is a treatment for the rare, progressive condition, and people with the disease watch their symptoms worsen over time. Any holdup between the funding decision and the first prescription costs them function they cannot get back. Patient advocates say the reimbursement step was meant to open the door, not to start another round of waiting. At the moment, families affected by the disease are left asking when the drug will actually become available to them.